MSM (Methylsulfonylmethane) is a naturally occurring organosulfur compound often used as a dietary supplement for its anti-inflammatory and antioxidant effects. While most well-known for joint health.
-MSM is actually a metabolite of DMSO (dimethyl sulfoxide)
-Generally Recognized as Safe Possible Interactions: aspirin, warfarin, NSAIDS
-Supplement dosage: 500mg 2-3times/day
-Anti-inflammatory: ↓NF-κB, ↓COX-2 and iNOS
-↓STAT3
-↓Cyclin D1 and CDK4, halting cell cycle progression.
-↓MMP-2, MMP-9, VEGF limiting invasion.
Methylsulfonylmethane (MSM) — Cancer-Oriented Time-Scale Flagged Pathway Table
| Rank |
Pathway / Axis |
Cancer / Tumor Context |
Normal Tissue Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NF-κB inflammatory transcription |
NF-κB ↓; COX-2/cytokines ↓ (reported) |
Inflammation tone ↓ |
R, G |
Anti-inflammatory signaling |
One of the most consistent findings in MSM studies is suppression of NF-κB-linked inflammatory signaling. |
| 2 |
STAT3 signaling |
STAT3 phosphorylation ↓ (reported) |
↔ |
R, G |
Pro-survival pathway suppression |
STAT3 inhibition has been reported in some breast and other tumor models; relevance depends on tumor type. |
| 3 |
PI3K / AKT pathway |
AKT signaling ↓ (reported; model-dependent) |
↔ |
R, G |
Growth modulation |
Observed in certain cell lines; should be presented as context-dependent rather than universal. |
| 4 |
ROS / redox modulation |
ROS ↓ (often); oxidative stress tone ↓ |
Oxidative injury ↓ |
P, R, G |
Redox buffering |
MSM is generally described as anti-oxidative/anti-inflammatory rather than pro-oxidant; not a ROS-amplifying therapy. |
| 5 |
Apoptosis induction |
Caspases ↑; Bax ↑; Bcl-2 ↓ (reported) |
↔ |
G |
Cell death signaling |
Apoptotic effects reported in vitro; usually downstream of inflammatory and survival pathway suppression. |
| 6 |
Cell-cycle regulation |
Cell-cycle arrest ↑ (reported) |
↔ |
G |
Cytostasis |
Observed in some cancer cell systems; mechanism linked to signaling changes. |
| 7 |
Migration / invasion (MMPs) |
MMP expression ↓; migration ↓ (reported) |
↔ |
G |
Anti-invasive phenotype |
Reduction in metastasis markers reported in certain preclinical models. |
| 8 |
ER stress modulation |
Stress signaling modulation (context-dependent) |
Proteostasis support |
R, G |
Stress pathway modulation |
Less consistent than NF-κB effects; should be kept qualified. |
| 9 |
Chemo-/radiation interaction (theoretical) |
May reduce inflammatory toxicity; may blunt ROS-based therapies |
Normal tissue protection possible |
G |
Adjunct positioning |
Because MSM is anti-oxidative/anti-inflammatory, positioning with strong pro-oxidant therapies should be considered carefully. |
| 10 |
Translation constraint |
Human anti-cancer efficacy not established |
Generally well tolerated in common supplement ranges |
— |
Evidence limitation |
Evidence base is largely preclinical; clinical oncology data are limited. |
Time-Scale Flag (TSF): P / R / G
- P: 0–30 min (early redox/inflammatory signaling shifts)
- R: 30 min–3 hr (NF-κB / STAT3 pathway modulation)
- G: >3 hr (cell-cycle, apoptosis, invasion phenotype changes)
For Alzheimer's (AD):
Methylsulfonylmethane (MSM) in neurobiology is primarily framed as an anti-inflammatory and redox-buffering molecule, not a direct amyloid-clearing or tau-targeting drug. Evidence is largely preclinical (cell + animal models). Position it as a neuroinflammation and oxidative stress modulator.
-Anti-inflammatory: ↓TNF-α, IL-1β, IL-6
-↓ROS, ↑GSH, ↓NO
-may reduce Aβ plaque burden and tau hyperphosphorylation indirectly
-improves memory in rodents
Methylsulfonylmethane (MSM) — Alzheimer’s Disease (AD) Time-Scale Flagged Pathway Table
| Rank |
Pathway / Axis |
AD / Brain Context |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
Neuroinflammation (NF-κB / cytokine signaling) |
Microglial activation ↓; IL-1β/TNF-α ↓ (reported) |
R, G |
Anti-inflammatory modulation |
MSM’s most consistent neuro-relevant signal is suppression of NF-κB-driven inflammatory tone, which is implicated in AD progression. |
| 2 |
Oxidative stress / redox buffering |
Lipid peroxidation ↓; ROS tone ↓ (reported) |
R, G |
Neuroprotection (stress buffering) |
MSM is generally described as antioxidant/anti-inflammatory rather than pro-oxidant; may help mitigate oxidative injury. |
| 3 |
Mitochondrial function support |
Mitochondrial stress ↓ (context-dependent) |
R, G |
Bioenergetic stabilization |
Indirect support through reduced oxidative and inflammatory burden; not a primary mitochondrial activator. |
| 4 |
ER stress / proteostasis modulation |
UPR signaling ↓ (reported in stress models) |
R, G |
Proteostasis buffering |
ER stress is relevant in AD pathology; MSM may attenuate stress signaling in some models. |
| 5 |
Calcium homeostasis modulation |
Excitotoxic stress ↓ (indirect) |
P, R |
Signal stabilization |
Primarily indirect via inflammatory and oxidative stress reduction. |
| 6 |
Aβ pathology (direct evidence) |
Limited direct evidence of amyloid reduction |
G |
Indirect modulation |
If effects occur, they are likely secondary to reduced oxidative stress and inflammation rather than direct amyloid targeting. |
| 7 |
Tau phosphorylation |
Limited direct mechanistic evidence |
G |
Indirect modulation |
No strong mechanistic evidence that MSM directly modulates tau kinases; effects likely indirect. |
| 8 |
Blood–brain barrier (BBB) considerations |
CNS exposure plausible but not strongly quantified |
R |
PK consideration |
Systemic exposure is good; CNS-specific pharmacokinetics are less clearly defined. |
| 9 |
Cognitive outcome evidence |
Limited direct human AD trial data |
— |
Translation constraint |
Evidence base is largely mechanistic/preclinical; clinical AD efficacy not established. |
Time-Scale Flag (TSF): P / R / G
- P: 0–30 min (early redox/inflammatory signaling shifts)
- R: 30 min–3 hr (microglial signaling + oxidative stress modulation)
- G: >3 hr (phenotype-level neuroprotection effects)
|